ERIS Lifesciences Ltd
ERIS Lifesciences Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Domestic Branded Formulations (DBF) business expects 12% revenue growth for FY26, with Q3 showing 10% growth and 13-14% growth expected for the full year excluding non-core brands. Eris Lifesciences forecasts 12% revenue growth in Domestic Branded Formulations (DBF) for FY26 with a 37% operating margin.
From ERIS Lifesciences Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Domestic Branded Formulations (DBF) business expects 12% revenue growth for FY26, with Q3 showing 10% growth and 13-14% growth expected for the full year excluding non-core brands.
- DBF segment targets a 37% operating margin this year and 39%+ EBITDA margin next year.
- Significant market share gains in the RHI insulin cartridge segment: from 8% at acquisition to 25-26% by Dec-Jan, with further growth expected in the RHI plus Glargine segment over the next 3 years.
- International business delivered 45% revenue growth in Q3, with strong visibility for FY27 revenue between INR 550-600 crores.
- CDMO revenue expected to grow, with INR 125-160 crore anticipated next year and full commercialization of a INR 1,000 crore order book over three years.
- Launch of GLP-1 products (Semaglutide) expected to drive growth, with initial margin pressure but overall positive top-line impact.
2 more points management made on revenue & sales performance
Profitability & Margins
See what ERIS Lifesciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ongoing capital investments are focused on Injectables, Insulin, Monoclonal Antibodies (MABs), and GLP-1 segments, continuing as per guidance (Page 16).
- CapEx for FY26 Q3 was about INR 80 crore, with nine-month CapEx around INR 200 crore, targeting Insulin, GLP-1, and Injectable projects (Page 5).
- The 3-year CapEx guidance remains around INR 200-250 crore per annum, totaling approximately INR 750 crore for FY26-FY28 (Pages 5 and 6).
- Investment front-loaded to capitalize on strategic opportunities in Injectable Insulin and GLP segments (Page 6).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what ERIS Lifesciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The current CDMO order book stands at an annualized size of INR 1,000 crore as of Q3FY26.
- This INR 1,000 crore order book is additional to the existing base business, primarily from the Swiss facility.
- The full commercialization and execution of this INR 1,000 crore order book is expected to take about three years.
- For the next year (FY27), the company expects CDMO revenues of INR 125-160 crore.
- The company has strong visibility of FY27 as a breakout year for international revenues, targeting INR 550-600 crore.
2 more points management made on order book & pipeline
ERIS Lifesciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹757 Cr, net profit ₹279 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What ERIS Lifesciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q3 FY26)
180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Morepen Laboratories Ltd (Q3 FY26)
488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were ERIS Lifesciences Ltd Q3 FY26 results?
Domestic Branded Formulations (DBF) business expects 12% revenue growth for FY26, with Q3 showing 10% growth and 13-14% growth expected for the full year excluding non-core brands. Eris Lifesciences forecasts 12% revenue growth in Domestic Branded Formulations (DBF) for FY26 with a 37% operating margin.
What is ERIS Lifesciences Ltd share price analysis?
ERIS Lifesciences Ltd currently shows a neutral. The stock trades at a P/E of 29.1 with a market cap of ₹19,057 Cr. Investors should review the full earnings analysis for detailed insights.
Is ERIS Lifesciences Ltd planning capital expenditure?
Ongoing capital investments are focused on Injectables, Insulin, Monoclonal Antibodies (MABs), and GLP-1 segments, continuing as per guidance (Page 16).
Keep ERIS Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.